Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated…
Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performanceParis, October 25, 2024Q3 sales growth of 15.7% at CER and business EPS (1)of €2.86Dupixent sales up 23.8% to €3,476 million; full-year 2024 target of ~€13 billion confirmedPharma launches up 67.1% to €727 million, led by ALTUVIIIO, Nexviazyme and RezurockVaccines sales up 25.5%, boosted by phasing of flu sales, and by...
Nasdaq GlobeNewswire
25/10/2024
Independent meta-analyses by Melanoma Institute of Australia on CP-GEP model in…
The MIA-led study analyzed data from independent external validation studies on the Merlin CP-GEP model published between 2020 and 2024. These studies spanned patient records from 4 countries, offering a comprehensive view of the model's predictive accuracy. The analysis revealed that the CP-GEP model achieved a sensitivity of 93%, meaning it accurately identified 93% of patients with nodal metastasis, while achieving an NPV (Negative Predictive Value) of 95%, indicating that 95% of patients…
PR Newswire
24/10/2024
Global Protein Chip Market to Surge at a CAGR of ~7% by 2030 | DelveInsight
Key Takeaways from the Protein Chip Market Report Key Takeaways from the Protein Chip Market Report To read more about the latest highlights related to the protein chip market, get a snapshot of the key highlights entailed in the Global Protein Chip Market Report Protein Chip Overview A protein chip, also known as a protein microarray, is a high-throughput platform used to study protein interactions, function, and expression on a large scale. It consists of thousands of...
PR Newswire
24/10/2024
IVD Assay Development Market to be Worth $8.39 Billion by 2031--Exclusive Report…
The IVD assay development market is projected to reach $8.39 billion by 2031, at a CAGR of 7.9% from 2024 to 2031. The IVD assay development market is projected to reach$8.39 billionby 2031, at a CAGR of 7.9% from 2024 to 2031. Download FREE PDF Brochure Of IVD Assay Development Market - https://www.meticulousresearch.com/download-sample-report/cp_id=6037 In vitro diagnostics (IVD) assay development services provide comprehensive, end-to-end contracting solutions. These services...
PR Newswire
24/10/2024
Pediatric Orphan Drug Market Size to Grow USD 102180 Million by 2030 at a CAGR…
Get Free Sample: https://reports.valuates.com/request/sample/QYRE-Auto-26J17580/Global_Pediatric_Orphan_Drug_Market_Research_Report_2024 Get Free Sample :https://reports.valuates.com/request/sample/QYRE-Auto-26J17580/Global_Pediatric_Orphan_Drug_Market_Research_Report_2024 Major Factors Driving the Growth of Pediatric Orphan Drug Market: The Pediatric Orphan Drug Market is poised for significant growth in the coming years as the demand for specialized treatments for rare pediatric...
PR Newswire
24/10/2024
Inside information: Orion terminates ODM-111 development program due to narrow…
ORION CORPORATIONSTOCK EXCHANGE RELEASE – INSIDE INFORMATION 24 OCTOBER 2024 at 19.50 EEST Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule Orion Corporation has decided to terminate the ODM-111 development program based on the risk-benefit analysis on the results of a longer non-clinical toxicology study. Recent findings indicate that the profile of the ODM-111 molecule does not support long-term use of ODM-111...
Nasdaq GlobeNewswire
24/10/2024
GUERBET : Revenue at September 30, 2024.
Revenue at September 30, 2024Continued growth momentum 9-month revenue: €620.5m, up 9.6% at CER 1 In the third quarter, momentum remained strong (+5.4% at CER), driven by the Americas (+13.1%) and Asia (+8.1%), while performance in EMEA (-2.3%) was once again impacted by the continued implementation of the new supply chain in France2024 annual targets confirmedRevenue: expected growth of over 9% on a like-for-like basis and at CERProfitability:...
Nasdaq GlobeNewswire
24/10/2024
ONWARD® Medical Publishes Prospectus for Listing of New Shares
THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, Oct.24, 2024(GLOBE NEWSWIRE) --ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today that it has published a...
Nasdaq GlobeNewswire
24/10/2024
Organoids Market Size To Reach $15.01 Billion By 2031 | CAGR 22.3%: The Insight…
Browse Detailed Analysis: https://www.theinsightpartners.com/reports/organoids-market Browse Detailed Analysis:https://www.theinsightpartners.com/reports/organoids-market Overview of Report Findings Market Growth : The organoid market is expected to reach U.S. $ 15.01 billionby 2031 from U.S. $ 3.03 billionin 2023, registering a CAGR of 22.1% during the forecast period. Organoids are microscopic and self-organized 3D structures produced in vitro from stem cells. They...
PR Newswire
24/10/2024
Radiopharmaceuticals Market Size To Reach $26.51 Billion By 2031 | CAGR 14.4%…
The radiopharmaceuticals market encompasses a growing number of clinical trials in targeted therapy that are expected to gain prominence in the coming years. The radiopharmaceuticals market encompasses a growing number of clinical trials in targeted therapy that are expected to gain prominence in the coming years. Global radiopharmaceuticals market is recording significant growth owing to the surging incidences of chronic diseases such as lung diseases, cancer, stroke, Alzheimer's,...
PR Newswire
24/10/2024
Biologics Market Size To Reach $1,793.9 Billion By 2031 | CAGR 18.2%: The…
The global biologics market observing significant growth owing to the increasing occurrence of chronic diseases globally and surging preference for outsourcing biologics manufacturing operations. The biologics market entails an array of platforms and services that are expected to dominate the market in the coming years. The report carries out an in-depth analysis of market trends, key players, and future opportunities. The global biologics market observing significant growth owing to the...
PR Newswire
24/10/2024
Pharmaceutical Drying Equipment Market to Hit USD 8.18 Billion by 2029 with 7.1%…
Browse in-depth TOC on "Pharmaceutical Drying Equipment Market" Browse in-depth TOC on "Pharmaceutical Drying Equipment Market" 221 - Tables 52 - Figures 226 - Pages Based on type, the pharmaceutical drying equipment market is segmented into vacuum dryers, spray dryers, freeze dryers, fluidized bed dryers, and other dryers. Among these, in 2023, freeze dryer segment the fastest growing segment in the pharmaceutical drying equipment market. This is due to the increasing...
PR Newswire
24/10/2024
Mölnlycke® Health Care and Transdiagen announce research collaboration to drive…
James Harding, CEO, Transdiagen added "We are thrilled to be working with Mölnlycke on this R&D programme. This collaboration will allow Mölnlycke access to TDG's novel models to generate functional insights regarding the mode of action of innovative and biological wound treatment solutions. We believe this marks a new chapter in the approach to data driven, evidence-based product development for the treatment of complex wounds." James Harding, CEO, Transdiagen added "We are…
PR Newswire
24/10/2024
Shaklee, A Leader in Clean Wellness and Skincare, Expands into Australia
"Our entry into Australia is not just about opening a new market—it represents the beginning of the next era of growth for Shaklee," said Shaklee's Chairman and CEO, Roger Barnett. "We remain committed to our vision of building healthier communities and fostering true wellness around the world." "Our entry intoAustraliais not just about opening a new market—it represents the beginning of the next era of growth for Shaklee," said Shaklee's Chairman and CEO,Roger…
PR Newswire
24/10/2024
Frost & Sullivan Honors Industry Leaders with Prestigious 2024 Best Practices…
"Frost & Sullivan's Best Practices Awards recognize companies that lead the charge in driving growth and innovation," said Jeff Frigstad, Global Senior Vice President of Best Practices at Frost & Sullivan. "These forward-thinking organizations are at the forefront of emerging trends and are shaping the future of their industries. I am thrilled to congratulate our award recipients, whose accomplishments set the bar for excellence and inspire progress across sectors."…
PR Newswire
24/10/2024
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control…
The new FDA-funded collaboration builds on research performed by EpiVax during two previous FDA contracts that evaluated the immunogenicity risk of generic drug impurities. Under the first contract, EpiVax demonstrated the value of in silico and in vitro methods for immunogenicity risk assessment of two well-known generic peptide drugs. Under the second contract, EpiVax developed the What-if Machine (WhIM), an algorithm designed to perform iterative modifications to the amino acid sequence of a…
PR Newswire
24/10/2024
Philips and Medtronic advocacy partnership aims to help accelerate access to…
Both companies also join the newly established World Stroke Organization Advocacy CoalitionAmsterdam, the Netherlands– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke care is crucial to saving lives and reducing long-term disability. As leaders in stroke diagnosis and treatment, the two organizations are...
Nasdaq GlobeNewswire
24/10/2024
Coronado Research Limited announce appointment of Professor Jennifer…
Coronado Research CEO, Andrew MacGarvey said "I am delighted to add Jen to the Coronado team. As Chief Scientific Officer, she will ensure that our service offering remains true to our vision. She brings significant experience in novel methodologies, something that is key to evolving clinical trials. Jen will combine high-calibre research with commercial understanding to build out our service offerings to accelerate drug development and ensure new treatments better meet market needs."…
PR Newswire
24/10/2024
IMG Announces 2024 Leave Your Mark Grant Winners
"Mission of Hope is deeply grateful to be a recipient of IMG's Leave Your Mark Grant, which will help us continue to provide vital support and resources to those in need," said Mission of Hope's Chief Operating Officer, Drew Garrison. "This contribution empowers us to expand our impact in Haiti and the Dominican Republic and bring hope to more men, women, and children across the island." "Mission of Hope is deeply grateful to be a recipient of IMG's Leave Your Mark…
PR Newswire
24/10/2024
UPM Biomedicals launches FibGel™ the world's first injectable nanocellulose…
FibGel is customizable owing to its tunable properties that allow adjustable stiffness and the incorporation of additional components. This flexibility enables tailored solutions for varying clinical needs and holds promise in a wide range of medical applications, including soft tissue repair, orthopaedic treatments, aesthetics, drug delivery, and cell transplantation. With FibGel's biological safety evaluations in accordance with ISO 10993, it is an ideal component for companies developing…
PR Newswire
24/10/2024
The Oxford-Harrington Rare Disease Centre (OHC) Announces Inaugural 2024 Rare…
The OHC brings together world-leading research, expertise in therapeutics development and new financial models to advance solutions to critical challenges in rare diseases. The OHC brings together world-leading research, expertise in therapeutics development and new financial models to advance solutions to critical challenges in rare diseases. Each Scholar will receive £100,000 (UK) /$100,000(US andCanada ), personalised therapeutics development support from industry experts to help...
PR Newswire
24/10/2024
Press Release: Dupixent late-breaking positive phase 3 data in chronic…
Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease status Confirmatory data to support US regulatory resubmission by year-end; if approved, Dupixent would be the first new targeted treatment for people living with chronic spontaneous urticaria in more than 10 yearsMore than 300,000 people in the US suffer from chronic...
Nasdaq GlobeNewswire
24/10/2024
deepc and The AI Centre for Value-Based Healthcare enter partnership to…
The AI4VBH's goal is to speed up and improve diagnosis and care across a large number of care pathways including dementia, heart failure and cancer. Over the past five years, the AI4VBH has developed numerous platforms to provide secure access to high-quality electronic health data for the development of AI models and deployment of AI technology. deepc's partnership with the AI4VBH will be focused on providing technology, resources and expertise to support the continued development of new and…
PR Newswire
24/10/2024
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD)…
BiogenInc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer's Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid, Spain. The presentations will include updates on new scientific findings from Biogen's Alzheimer's portfolio, highlighting data on different aspects of treatment and data examining preclinical Alzheimer's disease and race. “These data showcase the breadth of our Alzheimer's disease research...
Nasdaq GlobeNewswire
24/10/2024
Altri Comunicati
